Table 1.
Association analysis of Siglec-15 expression with clinicopathological features of gastric cancer patients.
| Clinicopathological features | Siglec-15 (+) | Siglec-153 (-) | p | ||
|---|---|---|---|---|---|
| n (%) | n (%) | ||||
| Age (years) | |||||
| ≥60 | 30 (42.25%) | 6(8.45%) | 0.1073 | ||
| <60 | 23 (32.39%) | 12(16.90%) | |||
| Sex | |||||
| Female | 17(23.94%) | 7(9.86%) | >0.9999 | ||
| Male | 36(50.70%) | 11(15.49%) | |||
| Surgery | |||||
| Total gastrectomy | 24(33.80%) | 8(11.27%) | >0.9999 | ||
| Partial gastrectomy | 29(40.85%) | 10(14.08%) | |||
| Neoadjuvant treatment | |||||
| I | 49(69.01%) | 17(23.94%) | |||
| III | 4(5.63%) | 1(1.41%) | >0.9999 | ||
| Surgical staging (TNM) | |||||
| I - II | 10(14.08%) | 8(11.27%) | 0.0566 | ||
| III - IV | 43(60.56%) | 10(14.08%) | |||
| Surgical staging (TNM) | |||||
| II | 5(7.94%) | 7(11.11%) | 0.0075 | ||
| III | 42(66.67%) | 9(14.29%) | |||
| Lymph node involvement | |||||
| Yes | 36(50.70%) | 10(14.08%) | 0.3979 | ||
| No | 17(23.94%) | 8(11.27%) | |||
| Histological grade | |||||
| GI + GII | 32(45.07%) | 3(4.23%) | 0.0022 | ||
| GIII | 21(29.58%) | 15(21.13%) | |||
| Chemotherapy | |||||
| Yes | 28(39.44%) | 10(14.93%) | >0.9999 | ||
| No | 25(35.21%) | 8(11.27%) | |||
| Radiotherapy | |||||
| Yes | 15(21.13%) | 6(8.45%) | 0.7676 | ||
| No | 38(53.52%) | 12(16.90%) | |||
| Recurrence | |||||
| Yes | 15(20.29%) | 1(1.41%) | 0.0546 | ||
| No | 38(53.52%) | 17(23.94%) | |||
| Lauren classification | |||||
| Intestinal | 28(41.18%) | 6(8.82%) | 0.1684 | ||
| Diffuse | 22(32.35%) | 12(17.65%) | |||
| Angiolymphatic Invasion | |||||
| Detected | 25 (37.88%) | 3(4.55%) | 0.0412 | ||
| Not detected | 25 (37.88%) | 13 (19.70%) | |||
| H. pylori infection | |||||
| Yes | 7(11.29%) | 1(1.61%) | 38(61.29%) | 0.4267 | |
| No |
TNM, tumor-node-metastasis.